EXEL - Here's Why This Growth Stock Is Already My 2022 Winner
As Thanksgiving approaches, 2022 is coming to a close -- and what a year the stock market had. The S&P 500 is still down 21% year to date. Most growth stocks have taken a beating this year. But amid this downfall, some companies still shone, giving investors a glimpse of hope.
One such company is oncology drugmaker Exelixis (NASDAQ: EXEL) . Its star product has captured everyone's attention. But the company has more in store to drive growth in the coming years. Here are some reasons why this growth stock is my winner this year.
For further details see:
Here's Why This Growth Stock Is Already My 2022 Winner